Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 10 December 1996.
The in vitro (outside the human body) tests were conducted at the Infectious Disease Section of Albany Medical College (Albany, N.Y.) and determined that, with one billion Candida albicans organisms -- a substantially higher test challenge of organisms than typically studied -- MDI-P killed up to 99 percent of the fungal organisms in less than one minute at a dilution of one to 10,000. Studies are now being considered to assess the agent's in vivo (inside the human body) effectiveness in treating Candida- related disease. Additional tests at the college have confirmed previous findings of MDI-P's in vivo nontoxicity, following intravenous administration in mice.
Diseases associated with Candida albicans range from painful, more commonly acquired thrush and vaginal candidiasis to the infection of intravenous or catheter lines, leading ultimately to renal failure or Candida encephalitis. Current treatments for serious Candida albicans infections bear numerous toxic side effects, such as anaphylaxis (life-threatening hypersensitivity), thrombopenia (decrease in blood-clotting platelets), convulsions, chills and anemia.
Marlin Toombs, director and vice president of Medical Discoveries, indicated that the test results proved encouraging for a number of reasons. "Not only is there tremendous demand for a fast, effective and nontoxic solution to this painful and often difficult-to-treat microorganism, but also we have accomplished infection control at levels far above the industry standard and at a formula dilution beyond what many had anticipated," said Toombs. "With in vivo toxicity results continuing to support the safety of MDI-P, we have taken another important step toward formally submitting the product for federal approval and offering MDI-P to a market in need of new microbicidal treatments."
Medical Discoveries, Inc. is a development stage biotechnology company focused on commercialization of certain antibiotic and antiviral technologies and agents, including processes and equipment for the rapid sterilization of dental, veterinary and medical instruments.
CONTACT: Marlin Toombs, Vice President/Director of Medical Discoveries, Inc., 801-273-7388; or Madeleine Franco or Andrew Graft, 801-595-8611, both of Jordan Richard Assoc./ 07:00 EST
961210
PR961221
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .